Albertans with cystic fibrosis now have access to a new drug under public coverage. On Friday, the province announced it would begin covering Alyftrek, a once-daily medication that targets the underlying cause of cystic fibrosis in people with certain genetic mutations. There are more than 600 Albertans living with cystic fibrosis, the province said in a media release; the life-threatening genetic disease causes thick mucus to build in the lungs and other parts of the body and has no cure. “Living with cystic fibrosis can be challenging for patients and their families, especially when treatment options are limited. By expanding access to medications like Alyftrek, we’re helping more Albertans get the care they need to live healthier lives,” said Justin Wright, minister of primary and preventative health services. Alyftrek is an alternative to Tikafta, which Alberta began covering in 2021. The treatment will be available to eligible Albertans aged six and older.
